Windsor Group LTD Cuts Stock Position in Colgate-Palmolive (NYSE:CL)

Windsor Group LTD lessened its holdings in Colgate-Palmolive (NYSE:CL) by 7.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 3,256 shares of the company’s stock after selling 276 shares during the quarter. Windsor Group LTD’s holdings in Colgate-Palmolive were worth $230,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of CL. Krane Funds Advisors LLC bought a new position in shares of Colgate-Palmolive in the 2nd quarter valued at about $25,000. Julex Capital Management LLC purchased a new position in shares of Colgate-Palmolive during the third quarter worth approximately $27,000. Lipe & Dalton purchased a new position in shares of Colgate-Palmolive during the second quarter worth approximately $29,000. Enterprise Trust & Investment Co purchased a new position in shares of Colgate-Palmolive during the second quarter worth approximately $36,000. Finally, Manchester Financial Inc. purchased a new position in shares of Colgate-Palmolive during the second quarter worth approximately $46,000. Institutional investors and hedge funds own 76.06% of the company’s stock.

In other Colgate-Palmolive news, CFO Henning I. Jakobsen sold 858 shares of Colgate-Palmolive stock in a transaction on Monday, September 9th. The shares were sold at an average price of $74.60, for a total value of $64,006.80. Following the completion of the transaction, the chief financial officer now owns 39,031 shares of the company’s stock, valued at $2,911,712.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Ian M. Cook sold 17,750 shares of Colgate-Palmolive stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $68.72, for a total transaction of $1,219,780.00. Following the completion of the transaction, the chairman now directly owns 1,029,785 shares of the company’s stock, valued at approximately $70,766,825.20. The disclosure for this sale can be found here. Insiders have sold 567,548 shares of company stock valued at $40,703,240 over the last 90 days. 1.14% of the stock is currently owned by insiders.

NYSE CL opened at $68.23 on Tuesday. The company has a market capitalization of $58.37 billion, a PE ratio of 22.97, a P/E/G ratio of 4.48 and a beta of 0.75. The company has a fifty day moving average of $71.46 and a 200 day moving average of $71.68. Colgate-Palmolive has a 1 year low of $57.41 and a 1 year high of $76.41.

Colgate-Palmolive (NYSE:CL) last posted its earnings results on Friday, July 26th. The company reported $0.72 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.72. The company had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.88 billion. Colgate-Palmolive had a net margin of 14.77% and a negative return on equity of 10,821.98%. The firm’s quarterly revenue was down .5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.77 earnings per share. As a group, equities analysts predict that Colgate-Palmolive will post 2.83 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Wednesday, October 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Tuesday, October 22nd. This represents a $1.72 dividend on an annualized basis and a yield of 2.52%. Colgate-Palmolive’s dividend payout ratio is presently 57.91%.

A number of equities analysts have recently commented on CL shares. Piper Jaffray Companies started coverage on shares of Colgate-Palmolive in a research report on Tuesday, August 13th. They set an “overweight” rating on the stock. Morgan Stanley raised their target price on shares of Colgate-Palmolive from $72.00 to $74.00 and gave the stock an “equal weight” rating in a research report on Monday, July 29th. JPMorgan Chase & Co. reduced their target price on shares of Colgate-Palmolive from $78.00 to $76.00 and set a “neutral” rating on the stock in a research report on Monday, October 14th. Citigroup raised their target price on shares of Colgate-Palmolive from $77.00 to $79.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 20th. Finally, Berenberg Bank began coverage on shares of Colgate-Palmolive in a research report on Wednesday, October 16th. They set a “sell” rating and a $58.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have assigned a buy rating to the stock. Colgate-Palmolive presently has a consensus rating of “Hold” and a consensus target price of $73.40.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.

Recommended Story: Short Selling Stocks, A Beginner’s Guide

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.